AI in Medical Questionnaires: Innovations, Diagnosis, and Implications.

Publication date: Jun 23, 2025

This systematic review aimed to explore the current applications, potential benefits, and issues of artificial intelligence (AI) in medical questionnaires, focusing on its role in 3 main functions: assessment, development, and prediction. The global mental health burden remains severe. The World Health Organization reports that >1 billion people worldwide experience mental disorders, with the prevalence of depression and anxiety among children and adolescents at 2. 6% and 6. 5%, respectively. However, commonly used clinical questionnaires such as the Hamilton Depression Rating Scale and the Beck Depression Inventory suffer from several problems, including the high degree of overlap of symptoms of depression with those of other psychiatric disorders and a lack of professional supervision during administration of the questionnaires, which often lead to inaccurate diagnoses. In the wake of the COVID-19 pandemic, the health care system is facing the dual challenges of a surge in patient numbers and the complexity of mental health issues. AI technology has now been shown to have great promise in improving diagnostic accuracy, assisting clinical decision-making, and simplifying questionnaire development and data analysis. To systematically assess the value of AI in medical questionnaires, this study searched 5 databases (PubMed, Embase, Cochrane Library, Web of Science, and China National Knowledge Infrastructure) for the period from database inception to September 2024. Of 49,091 publications, a total of 14 (0. 03%) studies met the inclusion criteria. AI technologies showed significant advantages in assessment, such as distinguishing myalgic encephalomyelitis or chronic fatigue syndrome from long COVID-19 with 92. 18% accuracy. In questionnaire development, natural language processing using generative models such as ChatGPT was used to construct culturally competent scales. In terms of disease prediction, one study had an area under the curve of 0. 790 for cataract surgery risk prediction. Overall, 24 AI technologies were identified, covering traditional algorithms such as random forest, support vector machine, and k-nearest neighbor, as well as deep learning models such as convolutional neural networks, Bidirectional Encoder Representations From Transformers, and ChatGPT. Despite the positive findings, only 21% (3/14) of the studies had entered the clinical validation phase, whereas the remaining 79% (11/14) were still in the exploratory phase of research. Most of the studies (10/14, 71%) were rated as being of moderate methodological quality, with major limitations including lack of a control group, incomplete follow-up data, and inadequate validation systems. In summary, the integrated application of AI in medical questionnaires has significant potential to improve diagnostic efficiency, accelerate scale development, and promote early intervention. Future research should pay more attention to model interpretability, system compatibility, validation standardization, and ethical governance to effectively address key challenges such as data privacy, clinical integration, and transparency.

Open Access PDF

Concepts Keywords
Algorithms AI
China Artificial Intelligence
Global artificial intelligence
Psychiatric COVID-19
September diagnostic accuracy
Humans
medical questionnaires
Mental Disorders
questionnaire development
questionnaire-based prediction
SARS-CoV-2
Surveys and Questionnaires

Semantics

Type Source Name
disease IDO role
disease MESH mental disorders
disease MESH depression
disease MESH anxiety
disease MESH COVID-19 pandemic
drug DRUGBANK Methionine
disease MESH myalgic encephalomyelitis
disease MESH long COVID
disease MESH cataract
disease IDO quality
disease IDO intervention
disease MESH privacy
disease MESH anxiety disorders
drug DRUGBANK Gold
disease MESH obsessive compulsive disorder
disease MESH suicidal ideation
disease IDO symptom
disease MESH suicide
disease IDO process
disease IDO algorithm
drug DRUGBANK Flunarizine
disease MESH confusion
disease MESH sequelae
disease MESH bipolar disorders
disease MESH unipolar depression
disease MESH facial pain syndromes
disease MESH insomnia
disease MESH sleep apnea
disease MESH obstructive sleep apnea
drug DRUGBANK Saquinavir
disease MESH facial expressions
disease MESH sleep disorders
disease MESH low back pain
disease MESH chronic diseases
disease MESH cognitive impairment
disease MESH stroke
disease MESH educational attainment
disease MESH autism
disease MESH dementia
disease MESH cerebral palsy
disease MESH amyotrophic lateral sclerosis
pathway KEGG Amyotrophic lateral sclerosis
disease MESH locked in syndrome
drug DRUGBANK Isoxaflutole
pathway REACTOME Translation
disease MESH misdiagnosis
disease MESH missed diagnoses
disease MESH uncertainty
drug DRUGBANK Etoperidone
disease MESH dysthymia
disease MESH burnout
drug DRUGBANK Guanosine
disease MESH aids
drug DRUGBANK Coenzyme M
disease IDO history
disease MESH Barrett’s esophagus
disease MESH pulmonary tuberculosis
disease MESH Pathological myopia
disease MESH post traumatic stress disorder
drug DRUGBANK Diethylstilbestrol
disease MESH major depressive disorder
drug DRUGBANK Tenocyclidine
disease MESH lifestyles
disease MESH psychosis
disease MESH noncommunicable diseases
disease MESH rare diseases
drug DRUGBANK Sulpiride
disease MESH tetraplegia
disease MESH intellectual disability
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Fluorescein
disease MESH emergency
disease MESH Chronic pain
drug DRUGBANK Tricyclazole
pathway REACTOME Reproduction

Original Article

(Visited 9 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *